Contrast-Induced Rhabdomyolysis Occurring after ERCP in a Patient with Pancreatic Cancer: A Case Report

Area of Science:

• Nephrology
• Oncology
• Radiology

Background:

• Pancreatic cancer patients undergoing ERCP are at risk for complications.
• Contrast-induced rhabdomyolysis is a rare but serious adverse event.
• Early recognition and management are crucial for patient outcomes.

Purpose of the Study:

• To report a case of contrast-induced rhabdomyolysis in a pancreatic cancer patient post-ERCP.
• To highlight the diagnostic criteria and management challenges of this condition.
• To discuss the potential role of iodine-based contrast agents in rhabdomyolysis.

Main Methods:

• Case report presentation.
• Review of patient's clinical presentation, laboratory findings, and treatment course.
• Literature review on contrast-induced rhabdomyolysis.

Main Results:

• A patient with pancreatic cancer developed acute renal failure, weakness, and elevated creatine kinase levels after ERCP.
• The patient was diagnosed with contrast-induced rhabdomyolysis.
• Despite haemofiltration, the patient's condition deteriorated, leading to death.

Conclusions:

• Contrast-induced rhabdomyolysis is a life-threatening condition with a high mortality rate.
• Iodine-based contrast agents may contribute to rhabdomyolysis by impairing muscle blood flow.
• Renal replacement therapy does not significantly improve mortality in severe cases.